Clinical trial · Observational
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
Efficacy Evaluation and Recurrence Monitoring of Neoadjuvant Therapy and Adjuvant Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection. The exclusive MRD (Minimal residual disease) probe consists of an exclusive "molecular label" formulated according to the individual genome mutation profile and 21 critical tumor driver genes. By continuously monitoring each patient's ctDNA dynamics, changes in ctDNA concentration or ctDNA-MRD negative/positive results will serve as the primary indicators to assess the efficacy and prognosis of patients with esophageal squamous cell carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Minimal Residual Disease | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- MRD positive group
- label
- MRD negative group
Primary outcomes (1)
- measure
- pathological complete response (pCR)
- timeFrame
- immediately after surgery
- description
- No residual tumor is the esophagus or dissected lymph nodes.
Secondary outcomes (2)
- measure
- Recurrence-free survival (RFS)
- timeFrame
- 2 years
- description
- The time from date of diagnosis to the time of recurrence or death.
- measure
- Overall survival (OS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age range from 18 to 80 years old; * Patients diagnosed with locally advanced esophageal squamous cell carcinoma by imaging or pathological examination: cT2-4N1-3M0, cT3-4N0M0 II-IVA (including IVB stage with supraclavicular and abdominal lymph node metastasis); * Receive neoadjuvant therapy; * Must be able to obtain the patient's clinical information and clear pathological diagnosis results; * Able to cooperate with long-term follow-up, regular review, and blood sample collection; * Patients agree to participate in the tracking and follow-up of the group and provide follow-up information; * Must obtain the informed consent of the patient or their legal representative, and the patient has the ability to cooperate to complete the requirements of the study. Exclusion Criteria: * Patients with other cancers or severe illnesses that result in shorter survival than the trial follow-up period; * Received other treatments (such as radiotherapy, etc.) before receiving neoadjuvant therapy; * Have contraindications to chemotherapy; * Patients who received blood transfusions within three months prior to enrollment; * HIV-positive patients or those with other immune system deficiency diseases; * Pregnant patients; * Alcohol or drug abusers; * Other situations that the researchers believe may affect the experimental results or are unethical.
References
Publications (0)
Data not yet available